Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
27 Mars 2024 - 12:07AM
Business Wire
Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of
Directors decided on March 26, 2024 (CET) to propose candidates for
Board of Directors at the 148th Ordinary General Meeting of
Shareholders to be held on June 26, 2024.
Mr. Milano Furuta, currently president of the Japan Pharma
Business Unit (JPBU), will succeed Mr. Constantine Saroukos as
chief financial officer (CFO) effective April 1, 2024. Takeda will
propose Mr. Furuta as a new candidate for board director at the
Ordinary General Meeting of Shareholders. If approved by
shareholders, Mr. Furuta will join the Board effective June 26,
2024.
Mr. Constantine Saroukos, who expressed his intention to retire
as CFO, will leave the Board on June 26, 2024 upon the expiration
of his term.
Candidates for Directors Who Are Not
Audit and Supervisory Committee Members
Name
Category
Expected Role
Christophe Weber
Internal
Existing
Representative Director,
President & Chief Executive Officer
Andrew Plump
Internal
Existing
Director, President, Research
& Development
Milano Furuta
Internal
New
Director, Chief Financial
Officer
Masami Iijima
External
Existing
External Director, Chair of the
Board Meeting
Olivier Bohuon
External
Existing
External Director
Ian Clark
External
Existing
External Director
Steven Gillis
External
Existing
External Director
John Maraganore
External
Existing
External Director
Michel Orsinger
External
Existing
External Director
Miki Tsusaka
External
Existing
External Director
Emiko Higashi
External
New
External Director
The tenure for non-Audit and Supervisory
Committee director is one year.
Candidates for Directors Who Are Audit
and Supervisory Committee Members
Name
Category
Expected Role
Koji Hatsukawa
External
Existing
External Director, Audit and
Supervisory Committee Member
Yoshiaki Fujimori
External
Existing
External Director, Audit and
Supervisory Committee Member
Kimberly A. Reed
External
Existing
External Director, Audit and
Supervisory Committee Member
Jean-Luc Butel
External
New
External Director, Audit and
Supervisory Committee Member
The tenure for Audit and Supervisory
Committee director is two years.
Note:
- The role of the directors will be determined at the Board of
Directors meeting and the Audit and Supervisory Committee meeting
to be held after the 148th Ordinary General Meeting of
Shareholders.
- The members of the Nomination Committee and Compensation
Committee will be discussed and determined at the Board of
Directors meeting to be held after the 148th Ordinary General
Meeting of Shareholders.
- Ms. Asuka Miyabashira, currently head of the Neuroscience
Business Unit within JPBU, will assume the role of president of
JPBU, effective April 1, 2024.
About Takeda Takeda is focused on creating better health
for people and a brighter future for the world. We aim to discover
and deliver life-transforming treatments in our core therapeutic
and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience and
vaccines. Together with our partners, we aim to improve the patient
experience and advance a new frontier of treatment options through
our dynamic and diverse pipeline. As a leading values-based,
R&D-driven biopharmaceutical company headquartered in Japan, we
are guided by our commitment to patients, our people and the
planet. Our employees in approximately 80 countries and regions are
driven by our purpose and are grounded in the values that have
defined us for more than two centuries. For more information, visit
www.takeda.com.
Important Notice For the purposes of this notice, “press
release” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or
distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this release. This press release (including any oral
briefing and any question-and-answer in connection with it) is not
intended to, and does not constitute, represent or form part of any
offer, invitation or solicitation of any offer to purchase,
otherwise acquire, subscribe for, exchange, sell or otherwise
dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are
being offered to the public by means of this press release. No
offering of securities shall be made in the United States except
pursuant to registration under the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. This press release is being
given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the
recipient for information purposes only (and not for the evaluation
of any investment, acquisition, disposal or any other transaction).
Any failure to comply with these restrictions may constitute a
violation of applicable securities laws. The companies in which
Takeda directly and indirectly owns investments are separate
entities. In this press release, “Takeda” is sometimes used for
convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our”
are also used to refer to subsidiaries in general or to those who
work for them. These expressions are also used where no useful
purpose is served by identifying the particular company or
companies.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240321811422/en/
Media Contacts: Global Media Brendan Jennings
brendan.jennings@takeda.com +81 80-2705-8259
Takeda Pharmaceutical (NYSE:TAK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Takeda Pharmaceutical (NYSE:TAK)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024